JP7025426B2 - 造血前駆体キナーゼ１（ｈｐｋ１）阻害剤としてのアニリノピリミジンａｓ - Google Patents
造血前駆体キナーゼ１（ｈｐｋ１）阻害剤としてのアニリノピリミジンａｓ Download PDFInfo
- Publication number
- JP7025426B2 JP7025426B2 JP2019528807A JP2019528807A JP7025426B2 JP 7025426 B2 JP7025426 B2 JP 7025426B2 JP 2019528807 A JP2019528807 A JP 2019528807A JP 2019528807 A JP2019528807 A JP 2019528807A JP 7025426 B2 JP7025426 B2 JP 7025426B2
- Authority
- JP
- Japan
- Prior art keywords
- amino
- alkyl
- chloro
- methoxy
- phenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 C*CC(C)C(*)(*)c1cc(Nc2ncc(*)c(Nc3c(*)cccc3)n2)c(*)cc1*C(C)C(C)* Chemical compound C*CC(C)C(*)(*)c1cc(Nc2ncc(*)c(Nc3c(*)cccc3)n2)c(*)cc1*C(C)C(C)* 0.000 description 10
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D455/00—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine
- C07D455/03—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing quinolizine ring systems directly condensed with at least one six-membered carbocyclic ring, e.g. protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine
- C07D455/04—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing quinolizine ring systems directly condensed with at least one six-membered carbocyclic ring, e.g. protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing a quinolizine ring system condensed with only one six-membered carbocyclic ring, e.g. julolidine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662428191P | 2016-11-30 | 2016-11-30 | |
| US62/428,191 | 2016-11-30 | ||
| PCT/US2017/063633 WO2018102366A1 (en) | 2016-11-30 | 2017-11-29 | Anilinopyrimidines as haematopoietic progenitor kinase 1 (hpk1) inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020503271A JP2020503271A (ja) | 2020-01-30 |
| JP2020503271A5 JP2020503271A5 (cg-RX-API-DMAC7.html) | 2021-01-07 |
| JP7025426B2 true JP7025426B2 (ja) | 2022-02-24 |
Family
ID=60629854
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019528807A Active JP7025426B2 (ja) | 2016-11-30 | 2017-11-29 | 造血前駆体キナーゼ１（ｈｐｋ１）阻害剤としてのアニリノピリミジンａｓ |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US11180482B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3548479A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7025426B2 (cg-RX-API-DMAC7.html) |
| MA (1) | MA46942A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2018102366A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (83)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112019019555A2 (pt) | 2017-03-30 | 2020-04-22 | Hoffmann La Roche | composto de fórmula i, composição farmacêutica, método de inibição de hpk1, método para melhorar uma resposta imune, método para tratar um distúrbio e uso do composto |
| WO2019090198A1 (en) | 2017-11-06 | 2019-05-09 | Bristol-Myers Squibb Company | Isofuranone compounds useful as hpk1 inhibitors |
| WO2020023551A1 (en) * | 2018-07-24 | 2020-01-30 | Genentech, Inc. | Naphthyridine compounds and uses thereof |
| CN112601584A (zh) * | 2018-07-24 | 2021-04-02 | 豪夫迈·罗氏有限公司 | 异喹啉化合物及其用途 |
| EP3856724A1 (en) * | 2018-09-30 | 2021-08-04 | F. Hoffmann-La Roche AG | Cinnoline compounds and for the treatment of hpk1-dependent disorders such as cancer |
| TW202024053A (zh) | 2018-10-02 | 2020-07-01 | 美商建南德克公司 | 異喹啉化合物及其用途 |
| US11612606B2 (en) | 2018-10-03 | 2023-03-28 | Genentech, Inc. | 8-aminoisoquinoline compounds and uses thereof |
| ES2979163T3 (es) | 2018-10-31 | 2024-09-24 | Gilead Sciences Inc | Compuestos de 6-azabenzimidazol sustituidos como inhibidores de HPK1 |
| WO2020092528A1 (en) * | 2018-10-31 | 2020-05-07 | Gilead Sciences, Inc. | Substituted 6-azabenzimidazole compounds having hpk1 inhibitory activity |
| EP3894406A1 (en) | 2018-12-11 | 2021-10-20 | Bayer Aktiengesellschaft | Substituted pyrrolopyridine-derivatives |
| MA55477A (fr) | 2019-03-26 | 2022-02-09 | Janssen Pharmaceutica Nv | Inhibiteurs de hpk1 |
| ES3031241T3 (en) | 2019-03-26 | 2025-07-07 | Janssen Pharmaceutica Nv | Bicyclic hpk1 inhibitors |
| EP3972695A1 (en) | 2019-05-23 | 2022-03-30 | Gilead Sciences, Inc. | Substituted exo-methylene-oxindoles which are hpk1/map4k1 inhibitors |
| KR102776925B1 (ko) | 2019-06-25 | 2025-03-11 | 길리애드 사이언시즈, 인코포레이티드 | Flt3l-fc 융합 단백질 및 사용 방법 |
| MA56462A (fr) * | 2019-07-04 | 2022-05-11 | Qilu Regor Therapeutics Inc | Inhibiteurs de hpk1 et leurs utilisations |
| WO2021004535A1 (en) * | 2019-07-11 | 2021-01-14 | Nanjing Zhengxiang Pharmaceuticals Co., Ltd. | Cinnolines as inhibitors of hpk 1 |
| CN110428982B (zh) * | 2019-07-31 | 2021-03-02 | 太仓碧奇新材料研发有限公司 | 一种超级电容器隔膜的制备方法 |
| BR112022004451A2 (pt) * | 2019-09-13 | 2022-06-21 | Nimbus Saturn Inc | Antagonistas de hpk1 e usos dos mesmos |
| CA3153501A1 (en) | 2019-10-18 | 2021-04-22 | Forty Seven, Inc. | Combination therapies for treating myelodysplastic syndromes and acute myeloid leukemia |
| CN114599392A (zh) | 2019-10-31 | 2022-06-07 | 四十七公司 | 基于抗cd47和抗cd20的血癌治疗 |
| TWI778443B (zh) | 2019-11-12 | 2022-09-21 | 美商基利科學股份有限公司 | Mcl1抑制劑 |
| AU2020406824A1 (en) * | 2019-12-16 | 2022-08-11 | Korea Research Institute Of Chemical Technology | Novel pyrimidine derivative and use thereof |
| EP4079726A4 (en) * | 2019-12-16 | 2024-01-24 | Korea Research Institute of Chemical Technology | NOVEL PYRIMIDINE DERIVATIVE AND USE THEREOF |
| PH12022551441A1 (en) | 2019-12-24 | 2023-11-20 | Carna Biosciences Inc | Diacylglycerol kinase modulating compounds |
| AR121047A1 (es) * | 2020-01-15 | 2022-04-13 | Blueprint Medicines Corp | Inhibidores de map4k1 |
| CR20220396A (es) | 2020-02-14 | 2022-11-14 | Jounce Therapeutics Inc | Anticuerpos y proteínas de fusión que se unen a ccr8 y usos de estos |
| EP4103182A4 (en) * | 2020-02-14 | 2024-02-21 | Salk Institute for Biological Studies | INHIBITORS OF ULK1/2 AND METHODS OF USE THEREOF |
| CA3171776A1 (en) * | 2020-04-14 | 2021-10-21 | Shansong ZHENG | Tricyclic compounds as egfr inhibitors |
| US20240043427A1 (en) | 2020-05-01 | 2024-02-08 | Gilead Sciences, Inc. | Cd73 compounds |
| JP2023527242A (ja) * | 2020-05-29 | 2023-06-27 | 南京正大天晴制薬有限公司 | Ａｘｌ阻害剤であるピリミジン系化合物 |
| WO2021249913A1 (en) | 2020-06-09 | 2021-12-16 | Bayer Aktiengesellschaft | 2'-(quinolin-3-yl)-5',6'-dihydrospiro[azetidine-3,4'-pyrrolo[1,2-b]pyrazole]-1-carboxylate derivatives and related compounds as map4k1 (hpk1) inhibitors for the treatment of cancer |
| CN116456985A (zh) * | 2020-09-23 | 2023-07-18 | 深圳市原力生命科学有限公司 | 作为hpk1调节剂的嘧啶及吡啶衍生物和其使用方法 |
| CN114437074A (zh) | 2020-11-03 | 2022-05-06 | 北京伯汇生物技术有限公司 | 一种化合物、含该化合物的药物组合物及其用途 |
| US20230416225A1 (en) * | 2020-11-09 | 2023-12-28 | Merck Sharp & Dohme Llc | Diaminopyrimidine carboxamide inhibitors of hpk1 |
| CN116438172A (zh) * | 2020-11-13 | 2023-07-14 | 南京红云生物科技有限公司 | Hpk1激酶调节剂、其制备方法与应用 |
| WO2022111517A1 (zh) * | 2020-11-24 | 2022-06-02 | 正大天晴药业集团股份有限公司 | 氘修饰的噻吩并吡啶酮化合物 |
| CN114805330A (zh) * | 2021-01-22 | 2022-07-29 | 苏州信诺维医药科技股份有限公司 | Hpk1抑制剂、其制备方法、药物组合物及其应用 |
| WO2022167627A1 (en) | 2021-02-05 | 2022-08-11 | Bayer Aktiengesellschaft | Map4k1 inhibitors |
| CN117295748A (zh) * | 2021-03-08 | 2023-12-26 | 缆图药品公司 | Map4k1抑制剂 |
| EP4305041A1 (en) * | 2021-03-08 | 2024-01-17 | Blueprint Medicines Corporation | Map4k1 inhibitors |
| WO2022199589A1 (zh) * | 2021-03-23 | 2022-09-29 | 南京明德新药研发有限公司 | 嘧啶衍生物 |
| WO2022199561A1 (zh) * | 2021-03-23 | 2022-09-29 | 杭州阿诺生物医药科技有限公司 | Hpk1激酶抑制剂化合物 |
| JP2024513011A (ja) | 2021-03-29 | 2024-03-21 | ニンバス サターン， インコーポレイテッド | Ｈｐｋ１アンタゴニスト及びその使用 |
| WO2022214008A1 (zh) * | 2021-04-08 | 2022-10-13 | 杭州阿诺生物医药科技有限公司 | 高活性hpk1激酶抑制剂 |
| TW202302145A (zh) | 2021-04-14 | 2023-01-16 | 美商基利科學股份有限公司 | ＣＤ４７／ＳＩＲＰα結合及ＮＥＤＤ８活化酶Ｅ１調節次單元之共抑制以用於治療癌症 |
| WO2022245671A1 (en) | 2021-05-18 | 2022-11-24 | Gilead Sciences, Inc. | Methods of using flt3l-fc fusion proteins |
| EP4359415A1 (en) | 2021-06-23 | 2024-05-01 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| CN117480155A (zh) | 2021-06-23 | 2024-01-30 | 吉利德科学公司 | 二酰基甘油激酶调节化合物 |
| CN117377671A (zh) | 2021-06-23 | 2024-01-09 | 吉利德科学公司 | 二酰基甘油激酶调节化合物 |
| EP4359413A1 (en) | 2021-06-23 | 2024-05-01 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| KR20240012538A (ko) * | 2021-07-06 | 2024-01-29 | 글렌마크 스페셜티 에스. 에이. | Map4k1 억제제로 사용하기 위한 피리미딘 화합물 |
| MX2024000751A (es) | 2021-07-14 | 2024-03-25 | Blueprint Medicines Corp | Compuestos heterociclicos como inhibidores de map4k1. |
| JP2024527623A (ja) | 2021-07-20 | 2024-07-25 | アストラゼネカ・アクチエボラーグ | 癌の治療のためのｈｐｋ１阻害剤としての置換ピラジン－２－カルボキサミド阻害剤 |
| CN115838373A (zh) * | 2021-09-18 | 2023-03-24 | 北京伯汇生物技术有限公司 | 氮杂吲唑大环化合物及其用途 |
| CN115838383A (zh) * | 2021-09-22 | 2023-03-24 | 南京正大天晴制药有限公司 | 作为axl抑制剂的苯并环庚烷类化合物 |
| AU2022375782A1 (en) | 2021-10-28 | 2024-05-02 | Gilead Sciences, Inc. | Pyridizin-3(2h)-one derivatives |
| EP4422756A1 (en) | 2021-10-29 | 2024-09-04 | Gilead Sciences, Inc. | Cd73 compounds |
| CN116178433A (zh) * | 2021-11-26 | 2023-05-30 | 南京正大天晴制药有限公司 | Axl激酶抑制剂的盐及其制备方法和用途 |
| CN116178434A (zh) * | 2021-11-26 | 2023-05-30 | 南京正大天晴制药有限公司 | Axl激酶抑制剂的单对甲苯磺酸盐及其晶型 |
| US20230203202A1 (en) | 2021-12-08 | 2023-06-29 | Dragonfly Therapeutics, Inc. | Proteins binding nkg2d, cd16 and 5t4 |
| US20230220106A1 (en) | 2021-12-08 | 2023-07-13 | Dragonfly Therapeutics, Inc. | Antibodies targeting 5t4 and uses thereof |
| WO2023122615A1 (en) | 2021-12-22 | 2023-06-29 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
| KR20240123836A (ko) | 2021-12-22 | 2024-08-14 | 길리애드 사이언시즈, 인코포레이티드 | 이카로스 아연 핑거 패밀리 분해제 및 이의 용도 |
| TW202340168A (zh) | 2022-01-28 | 2023-10-16 | 美商基利科學股份有限公司 | Ｐａｒｐ７抑制劑 |
| ES2999273T3 (en) | 2022-03-17 | 2025-02-25 | Gilead Sciences Inc | Ikaros zinc finger family degraders and uses thereof |
| AU2023240346A1 (en) | 2022-03-24 | 2024-09-19 | Gilead Sciences, Inc. | Combination therapy for treating trop-2 expressing cancers |
| TWI876305B (zh) | 2022-04-05 | 2025-03-11 | 美商基利科學股份有限公司 | 用於治療結腸直腸癌之組合療法 |
| CN119487038A (zh) | 2022-04-21 | 2025-02-18 | 吉利德科学公司 | Kras g12d调节化合物 |
| WO2024006929A1 (en) | 2022-07-01 | 2024-01-04 | Gilead Sciences, Inc. | Cd73 compounds |
| WO2024064668A1 (en) | 2022-09-21 | 2024-03-28 | Gilead Sciences, Inc. | FOCAL IONIZING RADIATION AND CD47/SIRPα DISRUPTION ANTICANCER COMBINATION THERAPY |
| EP4638436A1 (en) | 2022-12-22 | 2025-10-29 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| CN118184669B (zh) * | 2023-03-17 | 2025-09-23 | 北京伯汇生物技术有限公司 | 作为多靶点激酶抑制剂的大环化合物 |
| US20240383922A1 (en) | 2023-04-11 | 2024-11-21 | Gilead Sciences, Inc. | KRAS Modulating Compounds |
| WO2024220917A1 (en) | 2023-04-21 | 2024-10-24 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| WO2025006720A1 (en) | 2023-06-30 | 2025-01-02 | Gilead Sciences, Inc. | Kras modulating compounds |
| WO2025024663A1 (en) | 2023-07-26 | 2025-01-30 | Gilead Sciences, Inc. | Parp7 inhibitors |
| TW202519517A (zh) | 2023-07-26 | 2025-05-16 | 美商基利科學股份有限公司 | Ｐａｒｐ７抑制劑 |
| WO2025054530A1 (en) | 2023-09-08 | 2025-03-13 | Gilead Sciences, Inc. | Pyrimidine-containing polycyclic derivatives as kras g12d modulating compounds |
| WO2025054347A1 (en) | 2023-09-08 | 2025-03-13 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
| KR20250041906A (ko) * | 2023-09-19 | 2025-03-26 | (주)엠디바이오팜 | Hpk1 및 mlk3 저해 활성을 갖는 신규한 화합물 및 이를 함유하는 항암용 조성물 |
| US20250154172A1 (en) | 2023-11-03 | 2025-05-15 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| WO2025137640A1 (en) | 2023-12-22 | 2025-06-26 | Gilead Sciences, Inc. | Azaspiro wrn inhibitors |
| US20250376484A1 (en) | 2024-05-21 | 2025-12-11 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2011523646A (ja) | 2008-05-21 | 2011-08-18 | アリアド・ファーマシューティカルズ・インコーポレイテッド | キナーゼ阻害剤としてのリン誘導体 |
| JP2013539795A (ja) | 2010-10-14 | 2013-10-28 | アリアド・ファーマシューティカルズ・インコーポレイテッド | Ｅｇｆｒ発動性がんの細胞増殖の阻害方法 |
| WO2015038868A1 (en) | 2013-09-13 | 2015-03-19 | Cephalon, Inc. | Fused bicyclic 2,4-diaminopyrimidine derivatives |
| JP2017518336A (ja) | 2014-06-17 | 2017-07-06 | コリア リサーチ インスティチュート オブ ケミカル テクノロジーＫｏｒｅａ Ｒｅｓｅａｒｃｈ Ｉｎｓｔｉｔｕｔｅ Ｏｆ Ｃｈｅｍｉｃａｌ Ｔｅｃｈｎｏｌｏｇｙ | ピリミジン‐２，４‐ジアミン誘導体及びそれを有効成分として含有する抗癌用医薬組成物 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5262564A (en) | 1992-10-30 | 1993-11-16 | Octamer, Inc. | Sulfinic acid adducts of organo nitroso compounds useful as retroviral inactivating agents anti-retroviral agents and anti-tumor agents |
| AU2014361800B2 (en) * | 2013-12-13 | 2020-05-07 | Dana-Farber Cancer Institute, Inc. | Methods to treat lymphoplasmacytic lymphoma |
-
2017
- 2017-11-29 MA MA046942A patent/MA46942A/fr unknown
- 2017-11-29 WO PCT/US2017/063633 patent/WO2018102366A1/en not_active Ceased
- 2017-11-29 US US16/465,073 patent/US11180482B2/en active Active
- 2017-11-29 JP JP2019528807A patent/JP7025426B2/ja active Active
- 2017-11-29 EP EP17811814.7A patent/EP3548479A1/en not_active Withdrawn
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2011523646A (ja) | 2008-05-21 | 2011-08-18 | アリアド・ファーマシューティカルズ・インコーポレイテッド | キナーゼ阻害剤としてのリン誘導体 |
| JP2013539795A (ja) | 2010-10-14 | 2013-10-28 | アリアド・ファーマシューティカルズ・インコーポレイテッド | Ｅｇｆｒ発動性がんの細胞増殖の阻害方法 |
| WO2015038868A1 (en) | 2013-09-13 | 2015-03-19 | Cephalon, Inc. | Fused bicyclic 2,4-diaminopyrimidine derivatives |
| JP2017518336A (ja) | 2014-06-17 | 2017-07-06 | コリア リサーチ インスティチュート オブ ケミカル テクノロジーＫｏｒｅａ Ｒｅｓｅａｒｃｈ Ｉｎｓｔｉｔｕｔｅ Ｏｆ Ｃｈｅｍｉｃａｌ Ｔｅｃｈｎｏｌｏｇｙ | ピリミジン‐２，４‐ジアミン誘導体及びそれを有効成分として含有する抗癌用医薬組成物 |
Non-Patent Citations (1)
| Title |
|---|
| Reghavendra Achary et al.，Discovery of novel tetrahydroisoquinoline-containing pyrimidines as ALK inhibitors，Bioorganic & Medicinal Chemistry，vol.24, no.2，pp.207-219 |
Also Published As
| Publication number | Publication date |
|---|---|
| US20190382379A1 (en) | 2019-12-19 |
| WO2018102366A1 (en) | 2018-06-07 |
| EP3548479A1 (en) | 2019-10-09 |
| US11180482B2 (en) | 2021-11-23 |
| MA46942A (fr) | 2021-05-05 |
| JP2020503271A (ja) | 2020-01-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7025426B2 (ja) | 造血前駆体キナーゼ１（ｈｐｋ１）阻害剤としてのアニリノピリミジンａｓ | |
| AU2022201082B2 (en) | Benzimidazole compounds as c-Kit inhibitors | |
| TWI848925B (zh) | 肌旋蛋白激酶抑制劑 | |
| JP2020503297A (ja) | Ｃ−ｋｉｔ阻害剤としてのアミノチアゾール化合物 | |
| JP2018504432A (ja) | ユビキチン特異的プロテアーゼ７阻害物質としてのイソチアゾロピリミジノン、ピラゾロピリミジノン及びピロロピリミジノン | |
| JP2018504431A (ja) | ユビキチン特異的プロテアーゼ７阻害物質としてのチエノピリミジノン | |
| JP2023528074A (ja) | Ｇｐｒ６５のモジュレーターとしてのｎ－（フェニルアミノカルボニル）テトラヒドロ－イソキノリン及び関連する化合物 | |
| EP4304588A1 (en) | Compounds having tetrahydroindolizine-1-carboxamide as bcl-2 inhibitors | |
| AU2022205292A9 (en) | Aminothiazole compounds as c-kit inhibitors | |
| CN118974050A (zh) | 作为ras信号转导调节剂的稠合杂环化合物 | |
| CA3114259C (en) | Aminonorbornane derivative and manufacture method therefor and use thereof | |
| NZ795572A (en) | Benzimidazole compounds as c-Kit inhibitors | |
| NZ795575A (en) | Benzimidazole compounds as c-Kit inhibitors | |
| HK40091563A (zh) | 嘧啶酮类化合物及其用途 | |
| EA048076B1 (ru) | Соединения, содержащие тетрагидроиндолизин-1-карбоксамид в качестве ингибиторов bcl-2 | |
| CA3114259A1 (en) | Aminonorbornane derivative and manufacture method therefor and use thereof | |
| CN105899513A (zh) | 用于治疗神经病症的(杂)芳基咪唑类/吡唑类化合物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190730 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20201120 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20201120 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20210921 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20211220 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20220117 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20220210 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7025426 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313111 |
|
| R371 | Transfer withdrawn |
Free format text: JAPANESE INTERMEDIATE CODE: R371 |
|
| S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313111 |
|
| R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |